GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nika Pharmaceuticals Inc (OTCPK:NIKA) » Definitions » EV-to-Revenue

NIKA (Nika Pharmaceuticals) EV-to-Revenue : (As of Apr. 24, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Nika Pharmaceuticals EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Nika Pharmaceuticals's enterprise value is $1,026.37 Mil. Nika Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00 Mil. Therefore, Nika Pharmaceuticals's EV-to-Revenue for today is .

The historical rank and industry rank for Nika Pharmaceuticals's EV-to-Revenue or its related term are showing as below:

NIKA's EV-to-Revenue is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.27
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-04-24), Nika Pharmaceuticals's stock price is $1.00. Nika Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00. Therefore, Nika Pharmaceuticals's PS Ratio for today is .


Nika Pharmaceuticals EV-to-Revenue Historical Data

The historical data trend for Nika Pharmaceuticals's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nika Pharmaceuticals EV-to-Revenue Chart

Nika Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-Revenue
Get a 7-Day Free Trial - - - - -

Nika Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Nika Pharmaceuticals's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Nika Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nika Pharmaceuticals's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nika Pharmaceuticals's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Nika Pharmaceuticals's EV-to-Revenue falls into.


;
;

Nika Pharmaceuticals EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Nika Pharmaceuticals's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=1026.370/0
=

Nika Pharmaceuticals's current Enterprise Value is $1,026.37 Mil.
Nika Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nika Pharmaceuticals  (OTCPK:NIKA) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Nika Pharmaceuticals's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=1.00/0
=

Nika Pharmaceuticals's share price for today is $1.00.
Nika Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nika Pharmaceuticals EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Nika Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Nika Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
2269 Merrimack Valley Avenue, Henderson, NV, USA, 89044
Nika Pharmaceuticals Inc is a company involved in development and distribution of a variety of pharmaceutical products, including dietary supplements and antiviral drugs. It has acquired the exclusive rights for production and distribution of the dietary supplements Physiolong and Carotilen, as well as the drug TNG, which has been clinically tested on AIDS patients.